Dr. Lee on the Results of the ENTRATA Trial in Advanced RCC

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the phase II ENTRATA trial in advanced renal cell carcinoma (RCC).

Data presented at the 2019 ESMO Congress indicated that the addition of the glutaminase inhibitor telaglenastat to everolimus extended progression-free survival versus everolimus alone in patients with heavily pretreated advanced RCC, meeting the prespecified endpoint of the ENTRATA trial. In the trial, the median progression-free survival was 3.8 months in the combination arm versus 1.9 months in the monotherapy arm (HR, 0.64; 95% CI, 0.34-1.20; one-sided P = .079).

These data demonstrate proof-of-concept for telaglenastat and support the use of glutaminase inhibition as a potential treatment strategy in advanced RCC, says Lee. The role of glutaminase inhibition is being further evaluated in the ongoing phase II CANTATA study, in which patients with advanced or metastatic RCC are being randomized to either telaglenastat in combination with cabozantinib (Cabometyx) or placebo plus cabozantinib.